Year: 2024

Royal Vopak completes share buyback program 2024 10 December 2024, Rotterdam, the Netherlands  Today, Vopak announces the completion of its share buyback program to return EUR 300 million to shareholders as announced on February 14, 2024. In the period from February 14, 2024 up to and including December 9, 2024, a total of 7,924,438 ordinary shares, 6.30% of the company’s outstanding shares, were repurchased, at an average price of EUR 37.86 per share. After cancellation the total number of issued outstanding shares will amount to 117,816,148. Detailed information including all individual transactions can be found on this page on our website vopak.com/investors/share-buyback-program-2024. About Royal VopakRoyal Vopak helps the world flow forward. At ports around the world, we provide storage and infrastructure solutions for vital products...

Hamilton, Bermuda. December 10, 2024. The shares in Avance Gas Holding Ltd (ticker: “AGAS”) will be traded ex-dividend USD 3.50 as of today relating to the dividend for the third quarter of 2024. The dividend will be paid on December 23, 2024. For further information, please contact: Randi Navdal Bekkelund, CFO Email: ir@avnacegas.com Tel: +47 23 11 40 00 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Cutting-Edge Liquid Crystal Technologies Drive Breakthroughs in Vision Care and Smart Eyewear TAINAN, Taiwan, Dec. 10, 2024 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, and Liqxtal Technology Inc. (“Liqxtal”), a subsidiary of Himax dedicated to developing various liquid crystal optical components with exceptional design expertise, today jointly unveiled a series of cutting-edge, patented products, including Liqxtal® Graph, Liqxtal® Dim and Liqxtal® Pro-Eye, all featuring advanced tunable liquid crystal-based optical technologies for specialized applications in vision care and smart eyewear to be showcased at CES 2025, the world’s largest consumer electronics show, held in Las Vegas, Nevada, U.S.A....

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,690,000 shares of its common stock at a price to the public of $6.25 per share and pre-funded warrants to purchase 2,325,372 shares of common stock at a price of $6.249 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 2,402,305 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares and pre-funded warrants...

World-class safety performance reaffirms XPENG’s commitment to occupant and road user protectionGUANGZHOU, China, Dec. 10, 2024 (GLOBE NEWSWIRE) — XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese high-tech car company, proudly announces that its electric ultra-smart coupe SUV, the XPENG G6, has achieved a prestigious five-star safety rating from the Australasian New Car Assessment Program (ANCAP).This high rating underscores exceptional safety performance across key evaluation areas, including Adult Occupant Protection, Child Occupant Protection, Vulnerable Road User Protection, and Safety Assist. Equipped with advanced safety features, the G6 demonstrated impressive crash performance, excelling in side impact and oblique pole tests where it scored maximum points. The XPENG G6’s...

Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior lines of therapy Manageable safety profile with no high-grade cytokine release syndrome (CRS) and low rates of Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS); adverse events were resolved with standard treatment protocols Initial clinical data are consistent with clinical experience from UCLA trial of CART19/20, a product candidate with the same CAR construct as IMPT-314 that has demonstrated durable responses in a Phase 1 trial of patients with non-Hodgkin lymphomaSOUTH SAN FRANCISCO, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline...

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up MGX-001 bioengineered FVIII construct exhibited higher FVIII activity at similar integration rates compared to wild type FVIII construct in preclinical studies; program on track for IND filing in 2026 EMERYVILLE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented updated preclinical NHP data for its hemophilia A program in an oral presentation (link here) at the American Society of Hematology (ASH) 66th Annual Meeting and Exposition in San Diego. “The distinguishing feature of our gene editing...